AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

QTRX · NASDAQ · Medical - Devices

Quanterix (QTRX)

Builds Simoa and spatial biology tools for ultra-sensitive biomarker research and diagnostics.

$3.14

vs last close−0.05 (−1.43%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	31	31	32	34	35	34	30	24	40	44	36	33
Cost of revenue	12	15	14	12	16	13	14	13	23	24	21	20
Gross profit	19	16	18	22	20	21	16	11	17	20	16	13
	32	33	33	33	31	36	43	48	54	44	37	62
Research & development	8	7	7	8	8	8	10	9	8	9	7	8
	24	25	27	25	24	29	33	32	39	35	30	27
General & administrative	24	25	27	25	24	29	33	32	39	35	30	0
Other expenses	0	1	0	0	0	−1	0	8	7	0	0	27
Operating income	−13	−17	−15	−11	−12	−15	−26	−37	−37	−24	−22	−49
	6	5	4	4	4	3	3	7	1	1	4	0
Interest income	4	4	4	4	4	3	3	3	1	1	1	1
Other non-operating income	0	−2	−4	−4	−4	−3	−3	−8	−1	−1	−4	0
Income before tax	−7	−12	−11	−7	−8	−12	−23	−30	−36	−23	−18	−49
Income tax expense	0	0	0	0	0	0	−3	0	−2	0	0	0
Net income from continuing operations	−7	−12	−11	−7	−8	−12	−21	−30	−34	−23	−18	−49
Net income	−7	−12	−11	−7	−8	−12	−21	−30	−34	−23	−18	−49
EPS, basic	−$0.21	−$0.33	−$0.26	−$0.19	−$0.22	−$0.30	−$0.53	−$0.77	−$0.73	−$0.49	−$0.37	−$1.04
EPS, diluted	−$0.21	−$0.33	−$0.26	−$0.19	−$0.22	−$0.30	−$0.53	−$0.77	−$0.73	−$0.49	−$0.37	−$1.04
Weighted average shares, basic	38	38	38	38	38	39	39	39	46	47	47	47
Weighted average shares, diluted	38	38	38	38	38	39	39	39	46	47	47	47
EBITDA	−12	−12	−9	−5	−7	−8	−21	−27	−31	−16	−11	−49
Depreciation & amortization	1	4	2	2	1	4	2	3	5	7	6	0
EBIT	−13	−15	−11	−7	−8	−12	−23	−29	−36	−23	−18	−49